BiotechTube
VQ Biomedical

VQ Biomedical

San Diego, United States· Est.
vqbiomedical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

VQ Biomedical is pioneering a disruptive intravascular oxygenation catheter aimed at treating hospitalized patients with severe respiratory failure, such as ARDS. Its technology seeks to provide a safer, simpler, and less costly alternative to mechanical ventilation and VV-ECMO by performing gas exchange directly within the blood vessels. The company, led by a seasoned team with deep Duke University roots and medical device experience, is in the pre-clinical development stage, backed by venture capital and significant non-dilutive funding from BARDA and DARPA. Recent recognition in the MedTech Innovator 2025 cohort underscores its potential impact in the critical care space.

Acute Respiratory Distress Syndrome (ARDS)Respiratory Failure

Technology Platform

Minimally invasive intravascular catheter for direct blood oxygenation and carbon dioxide removal, designed to function independently of the lungs.

Opportunities

The technology addresses a large, high-cost unmet need in critical care, with the potential to create a new standard of care between mechanical ventilation and ECMO.
Non-dilutive funding from BARDA and DARPA provides significant capital and strategic validation, while the growing incidence of severe respiratory conditions presents a expanding market.

Risk Factors

The company faces high technical risk in developing a miniaturized, efficient, and safe intravascular oxygenator.
Regulatory pathway for this novel, high-risk device will be lengthy and require substantial clinical data.
Significant competition exists from established ECMO technologies and other novel lung-assist devices in development.

Competitive Landscape

Primary competitors are established technologies: mechanical ventilators (e.g., Philips, Medtronic, Getinge) and VV-ECMO systems (e.g., Getinge, LivaNova, Medtronic). Other startups are exploring alternative intravascular and paracorporeal lung assist devices, but VQ's specific intracorporeal approach is distinct and faces fewer commercialized direct competitors.

More companies in Biologics / Biosimilars →More companies in United States →